Praxis Precision Medicines Inc. (PRAX)
NASDAQ: PRAXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
PRAX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $7.76B
- EPS (TTM)
- -$12.95
- Dividend yield
- None
- 52-week range
- 50.56 – 392.70
- Day range
- 271.28 – 285.53
- Volume / Avg
- 444.15K / 404.98K
- Beta
- —
- Shares outstanding
- 27.92M
- Next earnings
- Nov 4, 2026
52-week range
PRAX stock today
Shares of Praxis Precision Medicines (PRAX) finished lower on Oct 7 at $278.02, a drop of 0.76% or $2.12 per share, versus the S&P 500's 0.22% decline. Shares are 29.2% below their 52-week high of $392.70, set on Aug 20, 2026 and 449.9% above the 52-week low of $50.56, in the middle of the past year's range. PRAX is down 5.7% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 434.2%.
Praxis Precision Medicines has posted a net loss over the last twelve months (EPS of -$12.95), so its P/E ratio is not meaningful. Praxis Precision Medicines's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Praxis Precision Medicines
Company profilePraxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Marcio Silva De'Souza M.B.A.
- Headquarters
- Boston, MA
- Employees
- 168
- IPO year
- 2020
- Website
- praxismedicines.com
Financial highlights
Full financialsIn fiscal 2025, Praxis Precision Medicines generated $0 in revenue, down 100.0% from fiscal 2024, the first decline in the 7 years shown. Praxis Precision Medicines reported a net loss of $303.3 million, compared with a loss of $182.8 million a year earlier. Diluted earnings per share came in at -$13.48.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $8.55M | $2.45M | $0 | — |
| Growth | -100.00% | +249.53% | — | — | — |
| Net income | $-303.27M | $-182.82M | $-123.28M | $-214.03M | $-167.06M |
| EPS (diluted) | $-13.48 | $-10.21 | $-18.69 | $-69.65 | $-3.94 |
Analyst forecast
ForecastConsensus (19 analysts)
strong_buy
Avg. price target
$644.42+131.79%
- Strong buy 3
- Buy 14
- Hold 1
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-3.66
- Last reported (Q2 2026)
- Aug 6, 2026
- EPS actual vs est.
- $-2.87 vs —
Praxis Precision Medicines peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ABVXAbivax SA ADR | 87.01 | -1.37% | $7.59B | vs PRAX |
| TGTXTG Therapeutics Inc. | 52.95 | +1.46% | $8.11B | vs PRAX |
| IONSIonis Pharmaceuticals Inc. | 44.16 | +0.36% | $7.34B | vs PRAX |
| CYTKCytokinetics Incorporated | 61.12 | -0.37% | $8.50B | vs PRAX |
| SYRESpyre Therapeutics Inc. | 80.85 | +0.92% | $7.13B | vs PRAX |
| ARWRArrowhead Pharmaceuticals Inc. | 61.48 | -0.10% | $8.68B | vs PRAX |
| ALKSAlkermes plc | 41.45 | -0.49% | $6.95B | vs PRAX |
| AMRXAmneal Pharmaceuticals Inc. Class A | 19.65 | -3.18% | $6.84B | vs PRAX |
Indexes, lists and sector
Praxis Precision Medicines stock FAQ
What is Praxis Precision Medicines's stock price today?
PRAX last traded at $278.02 as of Oct 7, 4:00 PM EDT, down 0.76% on the day. Prices are delayed at least 15 minutes.
Does Praxis Precision Medicines pay a dividend?
No. Praxis Precision Medicines does not currently pay a regular cash dividend.
When is Praxis Precision Medicines's next earnings date?
Praxis Precision Medicines is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-3.66.
Who is Praxis Precision Medicines's CEO?
Mr. Marcio Silva De'Souza M.B.A. is the chief executive officer of Praxis Precision Medicines Inc., which has about 168 employees.
Has PRAX ever split its stock?
Yes. The most recent PRAX stock split was a 1-for-15 split on Nov 29, 2023.
What is the PRAX 52-week high?
The 52-week high for PRAX is $392.70 and the 52-week low is $50.56. The stock is currently 29.2% below its high.